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and in general such differences were not systematic (e.g.
the result for Germany was not always more favourable
than that for the UK). However, if a cost-effectiveness
threshold (i.e. willingness-to-pay) for a life-year or QALY
of $50,000 were assumed, the implications for decision-
making would be similar across countries. CONCLU-
SIONS: It is concluded that, where the analyst allows
factors to vary, cost-effectiveness results differ by country.
However, the implications of such variation for decision-
making depend critically on the cost-effectiveness thresh-
olds applying in Europe.
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Therapeutic innovations are generating increasing pres-
sure on health care budgets particularly for hospitals.
Health care professionals are confronted with budgetary,
ethical and equity issues when no explicit criteria for
choice have been set by the community. Reviews of cost-
advantage proﬁle for costly innovations are rare. OBJEC-
TIVE: This work seeks to analyse propensity and capacity
of health systems to ﬁnance therapeutic innovations
according to their cost/advantages proﬁle. METHODS: A
literature review was carried out. A series of therapeutic
innovations addressing life-threatening conditions were
identiﬁed between 1988 and 2003. They were selected
according to: whether they were considered as innova-
tions at time of their introduction into the market and
their cost high. Forty-four publications in peer-reviewed
journals were selected. Innovations were classiﬁed
according to severity of the condition and the treatment
impact on vital prognosis and survival. Reported costs
were actualised to 2002 values. Common indicators
across studies were identiﬁed. RESULTS: The cost per
year of life saved (YLS) for breast cancer treated for com-
binations including paclitaxel in Europe varies between
€7800 and €14000; at 5 years, the cost for trastuzumab/
paclitaxel association is €23000 in UK. This is between
€7000 and €14000 for ovarian cancer. Cost per YLS 
for myocardial infarctus treated by alteplase in France 
is €12000. It varies between €45000 and €79000 
for implantable cardiac deﬁbrillators. This cost varies
between €10000 to €12000 in Europe and around
€12000 in France for drotrecogin alfa (activated) (recom-
binant human activated protein C) for treatment of severe
sepsis with multiple organ failure, recently launched in
France. CONCLUSIONS: Pharmaco-economic indicators
such as cost per YLS can assist payors in decision-making
process when confronted with costly innovations in
chronic and acute disease. A further step is to consider
the budget impact, taking into account criteria such as
incidence, prevalence, severity, and mortality.
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OBJECTIVES: Financing of hospital services in Germany
is presently transformed to a DRG-based system destined
to derive 100% of the hospital revenue. The aim of this
study is to determine whether the German DRG based
reimbursement provides adequate coverage of actual
costs of intensive care unit (ICU) patients. METHODS:
Retrospective analysis of ICU length of stay (LOS) and
direct cost data extracted from patients’ electronic
records from the surgical ICU of the University Hospital
Göttingen, Germany. Cost calculations performed for
1187 patients with LOS > 24 hours over a 24-month
period (January 1, 2000–Decemeber 31, 2001). ICU reim-
bursement calculations based on the speciﬁc G-DRG
according to the individual diagnosis and the ﬁxed ICU
proportion of the G-DRG reimbursement. Direct variable
cost (consumables) were assessed bottom-up by means of
a patient data management system. Personnel cost were
calculated per day of treatment. Actual total costs were
compared with the hypothetical DRG reimbursement.
RESULTS: Total actual cost for ICU services was €5.58
million (mean per patient: €4697), while the correspond-
ing DRG-based total reimbursement was €2.98 million
(mean per patient: €.513). The cost deﬁcit is statistically
signiﬁcant (P < 0.001). Underfunding of the costs was
evident in most DRG classiﬁcations, some with reim-
bursement deﬁcits of over 80%. These differences showed
a signiﬁcant and negative linear correlation with ICU LOS
(R = -0.593, p < 0.001). CONCLUSIONS: The computed
G-DRG based reimbursement for ICU services differed
signiﬁcantly from the actual costs incurred. These ﬁnd-
ings highlight the importance of a more realistic and fair
DRG-based reimbursement of hospital ICU services in
Germany, particularly with respect to patients with
extended LOS.
PHP7
PHARMACOECONOMICS IN HEALTH CARE-
DECISION MAKING: A SURVEY ON CHINA
HEALTH CARE SYSTEM
Yang L1, Hu S1, Mulligan AT2
1Fudan University, Shanghai, China; 2GSKChina, Shanghai, China
712 Abstracts
With the rapid Health care reform and increasing cost-
containment pressure on China’s health care system,
Chinese government authorities and hospital administra-
tors have focus more attention on the importance on
health economics to allocate the scarce resources more
efﬁciently. OBJECTIVE: The purpose of this study was
to identify key decision criterias and source of informa-
tion that government ofﬁcials, hospital administrators
and physicians perceive as important in drug pricing and
reimbursement process and establishing clinical practice
guidelines respectively. Moreover, obstacles to using phar-
macoeconomic evaluations in decision-making were also
identiﬁed. METHODS: Data were gathered through a
survey questionnaire administered to various members of
Health Authorities, Health Insurance Bureaus, State Food
and Drug Administrations and hospitals throughout
China. There were 390 member organisations of which
65% responded. Factor analysis CANOVA and Chi-
square test were applied. RESULTS: The ﬁndings indi-
cated that current Health care policies/guidelines supplied
by government authorities are considered the most impor-
tant source of information in decision making (mean
score 4.28) as opposed to clinical or industry input. Cost
Effectiveness arguments are considered the most impor-
tant decision criteria (mean score 4.22). Although there
was interest in pharmacoeconomics, these studies in
China were limited (90.2%) and insufﬁcient pharmaeco-
nomic knowledge among health administrators (89.0%).
There were also difﬁculties in translating study results
into practical health care administrative and clinical
usage. CONCLUSIONS: With the increasing interest and
need for Pharmacoeconomics in China’s Health care deci-
sion-making, training would be helpful in assisting gov-
ernment ofﬁcials and hospital staffs’ knowledge to make
cost-effective health care decision. Assessing global phar-
maeconomic guidelines would also be useful to pursuing
China’s pharmaeconomics interest.
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OBJECTIVES: To provide an outline of the European
Network of Health Economic Evaluation Databases
(EURO NHEED) project, whose purpose is to implement,
in 7 European centres based in France, Germany, Italy,
the Netherlands, Spain, Sweden and the United Kingdom,
databases on the economic evaluation of health care inter-
ventions. METHODS: The network is based on two
existing and well-established resources, namely the UK’s
NHS Economic Evaluation Database (NHS EED), and
France’s Connaissances et Décision en ÉConomie de la
Santé (CODECS) database. Steering and scientiﬁc com-
mittees have been established to guide methodological
and administrative developments throughout the imple-
mentation and eventual management of the project.
RESULTS: EURO NHEED is funded by the European
Commission for an initial period of 3 years, and 
covers 17 European countries. After full implementation
it will provide its users with bibliographic records, detail-
ing the main characteristics of all included studies. In
addition, structured s will be provided for articles iden-
tiﬁed as full economic evaluations (cost-beneﬁt, cost-
effectiveness or cost-utility), which will offer a detailed
critique of the ﬁndings and the methodology used. These
databases will be accessible free of charge on the Inter-
net. A common training programme has been conducted,
and a methodological guide produced which will ensure
consistency in the methods and practices adopted by 
participating centres. CONCLUSION: The EURO
NHEED project is the ﬁrst attempt to develop such a
resource on a multi-national basis. The project is bring-
ing together health economists and information scientists
from Europe and beyond to provide a number of bene-
ﬁts in the ﬁeld of Health Economics. These include har-
monisation and increased understanding regarding the
theory and methodology of economic evaluation, and
improved interpretation of the generalisability of studies.
The project will therefore advance the state of the art in
collecting, summarising, critiquing and disseminating
health economics evaluation studies conducted within
Europe.
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OBJECTIVES: In 1997, the Belgian reimbursement for
prophylaxis in surgery changed from FFS to a lump-sum
per operation. We investigate whether this altered the
medical practice w.r.t. the administration of prophylaxis.
METHODS: The entire population that had undergone
one of these six operations was included: endoscopic
resection of prostate, surgical treatment of discal hernia,
arthroplasty of hip with total prosthesis, reconstruction
of cruciate knee ligaments by arthroscopy, total hysterec-
tomy (abdominal) and total hysterectomy (vaginal),
accounting for 159,981 operations and a cost for antibi-
otics of €10853 million. Cluster analysis is performed 
to identify outliers, classify cases/patients with similar
antibiotic treatment, compare both periods, and condense
information. Different treatment patterns emerging from
the cluster analyses were examined to assess the appro-
priateness of the administered products. RESULTS: A
drastic and immediate change in medical practice: 11%
of the patients did not receive antibiotics anymore con-
trasting with the situation before, where all hospitals
administered antibiotics to all patients. Large differences
